CHK1 as a therapeutic target to bypass chemoresistance in AML.

The nucleoside analog cytarabine, an inhibitor of DNA replication fork progression that results in DNA damage, is currently used in the treatment of acute myeloid leukemia (AML). We explored the prognostic value of the expression of 72 genes involved in various aspects of DNA replication in a set of 198 AML patients treated by cytarabine-based chemotherapy. We unveiled that high expression of the DNA replication checkpoint gene CHEK1 is a prognostic marker associated with shorter overall, event-free, and relapse-free survivals and determined that the expression of CHEK1 can predict more frequent and earlier postremission relapse. CHEK1 encodes checkpoint kinase 1 (CHK1), which is activated by the kinase ATR when DNA replication is impaired by DNA damage. High abundance of CHK1 in AML patient cells correlated with higher clonogenic ability and more efficient DNA replication fork progression upon cytarabine treatment. Exposing the patient cells with the high abundance of CHK1 to SCH900776, an inhibitor of the kinase activity of CHK1, reduced clonogenic ability and progression of DNA replication in the presence of cytarabine. These results indicated that some AML cells rely on an efficient CHK1-mediated replication stress response for viability and that therapeutic strategies that inhibit CHK1 could extend current cytarabine-based treatments and overcome drug resistance. Furthermore, monitoring CHEK1 expression could be used both as a predictor of outcome and as a marker to select AML patients for CHK1 inhibitor treatments. Copyright © 2016, American Association for the Advancement of Science.

Citation

Laure David, Anne Fernandez-Vidal, Sarah Bertoli, Srdana Grgurevic, Benoît Lepage, Dominique Deshaies, Naïs Prade, Maëlle Cartel, Clément Larrue, Jean-Emmanuel Sarry, Eric Delabesse, Christophe Cazaux, Christine Didier, Christian Récher, Stéphane Manenti, Jean-Sébastien Hoffmann. CHK1 as a therapeutic target to bypass chemoresistance in AML. Science signaling. 2016 Sep 13;9(445):ra90

Mesh Tags

Substances

PMID: 27625304

search → result